Skip to content

Richard F Smith

Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin, Madison, WI, 53706, USA.

1 paper in the library · 10 citations · publishing 2024

Papers

Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.

Translational psychiatry September 12, 2024 Christopher R Nicholas, Matthew I Banks, Richard C Lennertz et al. 10 citations

Psilocybin, a serotonergic psychedelic, can relieve symptoms in several psychiatric disorders and improve well-being, but it was unclear whether these benefits arise during the acute experience or depend on later memory of it. In 8 healthy participants, psilocybin (25 mg) was co-administered with the amnestic benzodiazepine midazolam at a dose that allowed a conscious psychedelic experience while partially impairing memory for it. Higher midazolam doses and greater memory impairment tended to associate with lower salience, insight, and well-being from psilocybin. These results suggest memory plays a role in therapeutically relevant behavioral effects of psilocybin.